Semaglutide Structure
Source:pubchem
For Research Use Only – Not for Human or Veterinary Use
Product Summary
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist created by strategic amino-acid substitutions and a C18 fatty-diacid side-chain that confers albumin binding and resistance to dipeptidyl-peptidase-4 (DPP-4) degradation. These modifications extend plasma half-life and enable once-weekly pharmacology in pre-clinical models. Semaglutide 5 mg is supplied as a high-purity, lyophilized powder for in-vitro and exploratory in-vivo research on metabolic regulation, weight management, and cardiometabolic signaling.
Key Details
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight: 4113.6 g/mol
CAS Number: 910463-68-2
Potential Research Applications
- Metabolic & Endocrine Regulation
- Exploration of glucose-stimulated insulin secretion, gastric emptying kinetics, and appetite-control pathways in cellular and rodent models.
- Obesity & Type 2 Diabetes Studies
- Evaluation of chronic semaglutide exposure on body-weight reduction, hepatic steatosis, and HbA1c modulation in diet-induced obesity models.
- Cardiovascular & Inflammatory Profiling
- Investigation of endothelial protection, blood-pressure dynamics, and C-reactive-protein suppression mediated by GLP-1R activation.
- Signal-Transduction Mapping
- Dissection of downstream cAMP/PKA, PI3K/Akt, and MAPK cascades triggered by GLP-1 receptor engagement, aiding target-pathway elucidation.
Safety and Compliance
- Research Use Only
- Semaglutide 5mg is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.
- Regulatory Status
- Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.
- Liability
- Users assume full responsibility for determining the suitability of Semaglutide 5mg in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.
References
- Zhang, Q. et al. (2024). “Second-generation GLP-1 analogues: metabolic and cardiovascular insights.” Trends in Endocrinology & Metabolism, 35 (3), 185–197.
- Morales-Perez, A. & Singh, V. (2023). “Semaglutide mitigates steatosis and insulin resistance in high-fat-diet mice.” Metabolism Research, 18 (2), 90–101.
Disclaimer
All product information is provided for research and informational purposes only.
Semaglutide 5mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.
